Renal function outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study

Francesco Trevisani, Federico Di Marco, Daniele Raggi, Arianna Bettiga, Riccardo Vago, Alessandro Larcher, Alessandra Cinque, Andrea Salonia, Alberto Briganti, Umberto Capitanio, Andrea Necchi, Francesco Montorsi, Francesco Trevisani, Federico Di Marco, Daniele Raggi, Arianna Bettiga, Riccardo Vago, Alessandro Larcher, Alessandra Cinque, Andrea Salonia, Alberto Briganti, Umberto Capitanio, Andrea Necchi, Francesco Montorsi

Abstract

The use of pembrolizumab has been largely accepted in several advanced types of cancers. PURE 01 study (NCT02736266) enrolled consecutively 143 patients with muscle-invasive bladder cancer who received 3 cycles of pembrolizumab 200 mg every 3 weeks before planned radical cystectomy (RC). Clinical, pathological and laboratory data were collected to investigate the relationship between renal function, immunotherapy and cancer-related outcomes. Serum creatinine and estimated glomerular filtration rate (eGFR) using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine-equation 2009 were reported at baseline and after every cycle of pembrolizumab; the T stage from clinical classification TNM (cTNM) was stated before the treatment. Our analysis did not demonstrate a significant impairment of eGFR after any cycle of pembrolizumab, neither in the overall cohort nor in subgroups considering the T stages or the CKD G-categories according to K-DIGO 2012 classification. In conclusion, in neoadjuvant setting before RC our results suggest that pembrolizumab administration is safe for renal function preservation.

Keywords: acute kidney injury; bladder cancer; chronic kidney disease; immunotherapy; neoadjuvant therapy; renal function.

© 2021 UICC.

References

REFERENCES

    1. Peláez Bejarano A, Montero Pérez O, Inoriza Rueda A, Garrido Martínez MT. Interstitial nephritis with pembrolizumab: a case report and review. J Oncol Pharm Pract. 2020. Online ahead of print.
    1. Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol. 2020;31:435-446.
    1. Mroue A, Moujaess E, Kourie HR, Azar H, Finianos S, Chelala D. Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: a systematic review of the literature. Crit Rev Oncol Hematol. 2021;157:103169.
    1. Necchi A, Raggi D, Giannatempo P, et al. Can patients with muscle-invasive bladder cancer and fibroblast growth factor receptor-3 alterations still be considered for neoadjuvant pembrolizumab? A comprehensive assessment from the updated results of the PURE-01 study. Eur Urol Oncol. 2020;77(4):439-446.
    1. Necchi A, Raggi D, Gallina A, et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur Urol. 2020;77:439-446.
    1. Necchi A, Bandini M, Calareso G, et al. Multiparametric magnetic resonance imaging as a noninvasive assessment of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: preliminary findings from the PURE-01 study. Eur Urol. 2020;77:636-643.
    1. Briganti A, Gandaglia G, Scuderi S, et al. Surgical safety of radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab in patients with bladder cancer: prospective assessment of perioperative outcomes from the PURE-01 trial. Eur Urol. 2020;77:576-580.
    1. Necchi A, Raggi D, Gallina A, et al. Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer. Eur Urol. 2020;77:701-710.
    1. Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol. 2018;36:3353-3360.
    1. Bandini M, Gibb EA, Gallina A, et al. Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study. Ann Oncol. 2020;31:1755-1763.
    1. Chapter 1: Definition and classification of CKD. Kidney Int Suppl. 2013;3:19-62.
    1. Section 2: AKI definition. Kidney Int Suppl. 2012;2:19-36.
    1. Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019;25:1706-1714.
    1. van Dijk N, Gil-Jimenez A, Silina K, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020;26:1839-1844.
    1. Gao J, Navai N, Alhalabi O, et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020;26:1845-1851.
    1. Takenaka T, Kawai Y, Amano T. Immune checkpoint therapy in proteinuric kidney disease. Eur J Cancer. 2018;95:120-122.
    1. Herz S, Höfer T, Papapanagiotou M, et al. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. Eur J Cancer. 2016;67:66-72.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する